Sugi Predict

Sugi Predict / Compounds / SCHEMBL4125055

SCHEMBL4125055

SCHEMBL4125055

COc1ccc(Cn2nc(-c3ccc(F)cc3)ccc2=O)cc1

nearest known ligand 0.74

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.71
▸ SMN1; SMN2 Q16637 2/20 0.71
▸ MEN1 O00255 5/20 0.65
▸ KMT2A Q03164 5/20 0.65
▸ HDAC1 Q13547 2/20 0.58
▸ PDE4A P27815 1/20 0.55
▸ PDE4B Q07343 1/20 0.55
▸ PDE4C Q08493 1/20 0.55
▸ PDE4D Q08499 1/20 0.55
▸ TP53 P04637 1/20 0.53
▸ MET P08581 1/20 0.53
▸ KDM4E B2RXH2 2/20 0.53
▸ HSD17B10 Q99714 1/20 0.53
▸ ALDH1A1 P00352 1/20 0.50
▸ POLB P06746 1/20 0.50
▸ ASIC1 P78348 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23297211 1.00 MAPT (0.71) MAPTSMN1; SMN2MEN1KMT2AHDAC1
SCHEMBL23297212 0.93 MAPT (0.79) MAPTSMN1; SMN2MEN1KMT2AHDAC1
SCHEMBL23297309 0.89 HDAC1 (0.61) MAPTSMN1; SMN2MEN1KMT2AHDAC1
SCHEMBL23297238 0.88 MAPT (0.72) MAPTSMN1; SMN2MEN1KMT2AHDAC1
SCHEMBL23297331 0.88 MAPT (0.72) MAPTSMN1; SMN2MEN1KMT2AHDAC1
SCHEMBL23297307 0.87 MAPT (0.71) MAPTSMN1; SMN2MEN1KMT2AHDAC1
SCHEMBL31409833 0.87 MAPT (0.71) MAPTSMN1; SMN2MEN1KMT2AHDAC1
SCHEMBL23297266 0.87 MAPT (0.71) MAPTSMN1; SMN2MEN1KMT2AHDAC1
SCHEMBL23297368 0.87 PDE4B (0.71) MAPTSMN1; SMN2MEN1KMT2AHDAC1
SCHEMBL3841611 0.87 MAPT (0.70) MAPTSMN1; SMN2MEN1KMT2AHDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12240833-B2 Pyridazinone compounds and uses thereof EDGEWISE THERAPEUTICS, INC. (US) 2025-03-04 — — US disclosed
EP-3877367-B1 PYRIDAZINONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS INC (US) 2024-05-22 — — EP disclosed
US-20230338375-A1 SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES EDGEWISE THERAPEUTICS, INC. 2023-10-26 — — US disclosed
US-20230338375-A1 SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES EDGEWISE THERAPEUTICS, INC. 2023-10-26 — — US disclosed
US-20230048816-A1 PYRIDAZINONE COMPOUNDS AND USES THEREOF CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) 2023-02-16 — — US disclosed
US-11390606-B2 Pyridazinone compounds and uses thereof EDGEWISE THERAPECUTICS, INC. (US) 2022-07-19 — — US disclosed
WO-2021231630-A1 SUBSTITUTED PYRIDAZINONE FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES EDGEWISE THERAPEUTICS, INC. (US) 2021-11-18 — — WO disclosed
US-20210130327-A1 PYRIDAZINONE COMPOUNDS AND USES THEREOF CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) 2021-05-06 — — US disclosed
US-20210130327-A1 PYRIDAZINONE COMPOUNDS AND USES THEREOF CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) 2021-05-06 — — US disclosed
US-8173653-B2 Pyridiazinone derivatives for the treatment of tumours MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) 2012-05-08 — — US disclosed
US-8173653-B2 Pyridiazinone derivatives for the treatment of tumours MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) 2012-05-08 — — US disclosed
EP-1960370-B1 PYRIDIAZINONE DERIVATIVES FOR TUMOUR TREATMENT MERCK PATENT GMBH (DE) 2011-10-05 — — EP disclosed
US-20080293719-A1 Pyridiazinone Derivatives for the Treatment of Tumours MERCK PATENT GESELLSCHAFT (DE) 2008-11-27 — — US disclosed
US-20080293719-A1 Pyridiazinone Derivatives for the Treatment of Tumours MERCK PATENT GESELLSCHAFT (DE) 2008-11-27 — — US disclosed
WO-2007065518-A1 PYRIDIAZINONE DERIVATIVES FOR TUMOUR TREATMENT MERCK PATENT GMBH (DE) 2007-06-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230338375-A1 SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES IL6, MUSK, SMN1; SMN2 MAPT 1863/4885SMN1; SMN2 3/4885MEN1 4467/4885
US-12240833-B2 Pyridazinone compounds and uses thereof IL6, IL1B, IL1A MAPT 1810/4885SMN1; SMN2 9/4885MEN1 4368/4885
US-11390606-B2 Pyridazinone compounds and uses thereof IL6, IL1B, IL1A MAPT 1810/4885SMN1; SMN2 9/4885MEN1 4368/4885
US-20210130327-A1 PYRIDAZINONE COMPOUNDS AND USES THEREOF IL6, IL1B, IL1A MAPT 1810/4885SMN1; SMN2 9/4885MEN1 4368/4885
US-20230048816-A1 PYRIDAZINONE COMPOUNDS AND USES THEREOF IL6, IL1B, IL1A MAPT 1810/4885SMN1; SMN2 9/4885MEN1 4368/4885
US-20080293719-A1 Pyridiazinone Derivatives for the Treatment of Tumours MET, RET, ERBB2 MAPT 3648/4885SMN1; SMN2 3892/4885MEN1 167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.